CoChat
Sign Up
Cited by 2,836Cell death mechanisms and regulationCancer-related Molecular PathwaysFlavonoids in Medical Research

Apoptosis in cancer: from pathogenesis to treatment

Open access
Wong, Rebecca SY·2011·Journal of Experimental & Clinical Cancer Research
DOI 10.1186/1756-9966-30-87PMC PMC3197541
Open this paper in CoChat — free accountOpen PDF

Abstract

Apoptosis is an ordered and orchestrated cellular process that occurs in physiological and pathological conditions. It is also one of the most studied topics among cell biologists. An understanding of the underlying mechanism of apoptosis is important as it plays a pivotal role in the pathogenesis of many diseases. In some, the problem is due to too much apoptosis, such as in the case of degenerative diseases while in others, too little apoptosis is the culprit. Cancer is one of the scenarios where too little apoptosis occurs, resulting in malignant cells that will not die. The mechanism of apoptosis is complex and involves many pathways. Defects can occur at any point along these pathways, leading to malignant transformation of the affected cells, tumour metastasis and resistance to anticancer drugs. Despite being the cause of problem, apoptosis plays an important role in the treatment of cancer as it is a popular target of many treatment strategies. The abundance of literature suggests that targeting apoptosis in cancer is feasible. However, many troubling questions arise with the use of new drugs or treatment strategies that are designed to enhance apoptosis and critical tests must be passed before they can be used safely in human subjects.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1756-9966-30-87

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 94

  1. Bauer JH Hefand SL New tricks of an old molecule: lifespan regulation by p53 Aging Cell 2006 5 437 440 10.1111/j.1474-9726.2006.00228.x 16968311 PMC1592233 · DOI
  2. Gasco M Shami S Crook T The p53 pathway in breast cancer Breast Cancer Res 2002 4 70 76 11879567 PMC138723
  3. Rodrigues NR Rowan A Smith ME Kerr IB Bodmer WF Gannon JV Lane DP p53 mutations in colorectal cancers Proc Natl Acad Sci USA 1990 87 19 7555 7559 10.1073/pnas.87.19.7555 1699228 PMC54786 · DOI
  4. Morton JP Timpson P Karim SA Ridgway RA Athineos D Doyle B Jamieson NB Oien KA Lowy AM Brunton VG Frame MC Jeffry Evans TR Sansom OJ Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer PNAS 2010 107 1 246 251 10.1073/pnas.0908428107 20018721 PMC2806749 · DOI · Paper page
  5. Jensen M Engert A Weissinger F Knauf W Kimby E Poynton C Oliff IA Rummel MJ Österborg A Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukaemia Invest New Drugs 2008 26 2 139 149 10.1007/s10637-007-9106-z 18094935 · DOI
  6. Baritaki S Militello L Malaponte G Spandidos DA Salcedo M Bonavida B The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF-κB/Snail/RKIP/PTEN resistance loop in B-NHL cells: role in sensitization to TRAIL apoptosis Int J Oncol 2011 38 6 1683 1694 21455568
  7. Kerr JF Harmon BV Tomei LD, Cope FO Definition and incidence of apoptosis: an historical perspective Apoptosis: the molecular basis of cell death 1991 3 New York: Cold Spring Harbor Laboratory Press 5 29
  8. Kerr JFR Wyllie AH Currie AR Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics Br J Cancer 1972 26 239 257 10.1038/bjc.1972.33 4561027 PMC2008650 · DOI
  9. Merkle CJ Porth CM, Matfin G Cellular adaptation, injury, and death Pathophysiology: concepts of altered health states 2009 8 Philadelphia: Wolters Kluwer/Lippincott Williams and Wilkins 94 111
  10. Hacker G The morphology of apoptosis Cell Tissue Res 2000 301 5 17 10.1007/s004410000193 10928277 · DOI
  11. Saraste A Pulkki K Morphologic and biochemical hallmarks of apoptosis Cardiovascular Res 2000 45 528 537 10.1016/S0008-6363(99)00384-3 10728374 · DOI
  12. Ziegler U Groscurth P Morphological features of cell death News Physiol Sci 2004 19 124 128 10.1152/nips.01519.2004 15143207 · DOI
  13. Manjo G Joris I Apoptosis, oncosis, and necrosis. An overview of cell death Am J Pathol 1995 146 3 15 7856735 PMC1870771
  14. Kumar V Abbas AK Fausto N Aster JC Robins and Cotran: pathologic basis of disease 2010 8 Philadelphia: Saunders Elsevier 25 32
  15. Hengartner MO Apoptosis: corralling the corpses Cell 2000 104 325 328 11239389
  16. Vaux D Silke J Mammalian mitochondrial IAP-binding proteins Biochem Biophy Res Commun 2003 203 449 504 12729584
  17. McCarthy NJ Evan GI Methods for detecting and quantifying apoptosis Curr Top Dev Biol 1998 36 259 278 9342533
  18. Lavrik IN Golks A Krammer PH Caspases: pharmacological manipulation of cell death J Clin Invest 2005 115 2665 2672 10.1172/JCI26252 16200200 PMC1236692 · DOI
  19. Galluzi L Maiuri MC Vitale I Zischka H Castedo M Zitvogel L Kroemer G Cell death modalities: classification and pathophysiological implications Cell Death Differ 2007 14 1237 1266 10.1038/sj.cdd.4402148 17431418 · DOI · Paper page
  20. O'Brien MA Kirby R Apoptosis: a review of pro-apoptotic and anti-apoptotic pathways and dysregulation in disease J Vet Emerg Crit Care 2008 18 6 572 585 10.1111/j.1476-4431.2008.00363.x · DOI
  21. Schneider P Tschopp J Apoptosis induced by death receptors Pharm Acta Helv 2000 74 281 286 10.1016/S0031-6865(99)00038-2 10812970 · DOI
  22. Karp G Cell and molecular biology: Concepts and experiments 2008 5 John New Jersey: Wiley and Sons 653 657
  23. Danial NN Korsmeyer SJ Cell death: critical control points Cell 2004 116 2 205 219 10.1016/S0092-8674(04)00046-7 14744432 · DOI · Paper page
  24. Tsujimoto Y Finger LR Yunis J Nowell PC Croce CM Cloning of the chromosome breakpoint of neoplastic B cells with the t(14; 18) chromosome translocation Science 1984 226 1097 1099 10.1126/science.6093263 6093263 · DOI
  25. Reed JC Bcl-2 family proteins: regulators of apoptosis and chemoresistance in haematologic malignancies Semin Haematol 1997 34 9 19 9408956
  26. LaCasse EC Mahoney DJ Cheung HH Plenchette S Baird S Korneluk RG IAP-targeted therapies for cancer Oncogene 2008 27 48 6252 6275 10.1038/onc.2008.302 18931692 · DOI
  27. Ghobrial IM Witzig TE Adjei AA Targeting apoptosis pathways in cancer therapy CA Cancer J Clin 2005 55 178 194 10.3322/canjclin.55.3.178 15890640 · DOI
  28. Szegezdi E Fitzgerald U Samali Caspase-12 and ER stress mediated apoptosis: the story so far Ann NY Acad Sci 2003 1010 186 194 10.1196/annals.1299.032 15033718 · DOI
  29. Hanahan D Weinberg RA The hallmarks of cancer Cell 2000 100 57 70 10.1016/S0092-8674(00)81683-9 10647931 · DOI · Paper page
  30. Gross A McDonnell JM Korsmeyer SJ BCL-2 family members and the mitochondria in apoptosis Genes Dev 1999 13 1899 1911 10.1101/gad.13.15.1899 10444588 · DOI
  31. Minn AJ Vélez P Schendel SL Liang H Muchmore SW Fesik SW Fill M Thompson CB Bcl-x(L) forms an ion channel in synthetic lipid membranes Nature 1997 385 6614 353 357 10.1038/385353a0 9002522 · DOI
  32. Raffo AJ Perlman H Chen MW Day ML Streitman JS Buttyan R Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo Cancer Res 1995 55 4438 7671257
  33. Fulda S Meyer E Debatin KM Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression Oncogene 2000 21 2283 2294 11948412
  34. Miquel C Borrini F Grandjouan S Aupérin A Viguier J Velasco V Duvillard P Praz F Sabourin JC Role of bax mutations in apoptosis in colorectal cancers with microsatellite instability Am J Clin Pathol 2005 23 4 562 570 15743744
  35. Goolsby C Paniagua M Tallman M Gartenhaus RB Bcl-2 regulatory pathway is functional in chronic lymphocytic leukaemia Cytometry B Clin Cytom 2005 63 1 36 46 15624202
  36. Pepper C Hoy T Bentley DP Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance Br J Cancer 1997 76 7 935 938 10.1038/bjc.1997.487 9328155 PMC2228064 · DOI
  37. Levine AJ Momand J Finlay CA The p53 tumour suppressor gene Nature 1991 351 6326 453 456 10.1038/351453a0 2046748 · DOI
  38. Oren M Rotter V Introduction: p53--the first twenty years Cell Mol Life Sci 1999 55 9 11 10.1007/s000180050265 10065147 PMC11146882 · DOI
  39. Avery-Kiejda KA Bowden NA Croft AJ Scurr LL Kairupan CF Ashton KA Talseth-Palmer BA Rizos H Zhang XD Scott RJ Hersey P p53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation BMC Cancer 2011 11 203 10.1186/1471-2407-11-203 21615965 PMC3120805 · DOI
  40. Slatter TL Hung N Campbell H Rubio C Mehta R Renshaw P Williams G Wilson M Engelmann A Jeffs A Royds JA Baird MA Braithwaite AW Hyperproliferation, cancer, and inflammation in mice expressing a Δ133p53-like isoform Blood 2011 117 19 5166 5177 10.1182/blood-2010-11-321851 21411755 · DOI
  41. Vucic D Fairbrother WJ The inhibitor of apoptosis proteins as therapeutic targets in cancer Clin Cancer Res 2007 13 20 5995 6000 10.1158/1078-0432.CCR-07-0729 17947460 · DOI
  42. Wei Y Fan T Yu M Inhibitor of apoptosis proteins and apoptosis Acta Biochim Biophys Sin 2008 40 4 278 288 10.1111/j.1745-7270.2008.00407.x 18401525 · DOI
  43. Lopes RB Gangeswaran R McNeish IA Wang Y Lemoine NR Expression of the IAP protein family is dysregulated in pancreatic cancer cells and is important for resistance to chemotherapy Int J Cancer 2007 120 11 2344 2352 10.1002/ijc.22554 17311258 · DOI
  44. Vucic D Stennicke HR Pisabarro MT Salvesen GS Dixit VM MLIAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas Curr Biol 2000 10 1359 1366 10.1016/S0960-9822(00)00781-8 11084335 · DOI
  45. Ashhab Y Alian A Polliack A Panet A Ben Yehuda D Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern FEBS Lett 2001 495 56 60 10.1016/S0014-5793(01)02366-3 11322947 · DOI
  46. Chen Z Naito M Hori S Mashima T Yamori T Tsuruo T A human IAP-family gene, apollon, expressed in human brain cancer cells Biochem Biophys Res Commun 1999 264 847 854 10.1006/bbrc.1999.1585 10544019 · DOI
  47. Small S Keerthivasan G Huang Z Gurbuxani S Crispino JD Overexpression of survivin initiates haematologic malignancies in vivo Leukaemia 2010 24 11 1920 1926 10.1038/leu.2010.198 PMC2978276 20882051 · DOI
  48. Krepela E Dankova P Moravcikova E Krepelova A Prochazka J Cermak J Schützner J Zatloukal P Benkova K Increased expression of inhibitor of apoptosis proteins, Survivin and XIAP, in non-small cell lung carcinoma Int J Oncol 2009 35 6 1449 1462 19885569
  49. Fink SL Cookson BT Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells Infect Immun 2005 73 4 1907 1916 10.1128/IAI.73.4.1907-1916.2005 15784530 PMC1087413 · DOI
  50. Shen XG Wang C Li Y Wang L Zhou B Xu B Jiang X Zhou ZG Sun XF Downregulation of caspase-9 is a frequent event in patients with stage II colorectal cancer and correlates with poor clinical outcome Colorectal Dis 2010 12 12 1213 1218 10.1111/j.1463-1318.2009.02009.x 19604285 · DOI
  51. Devarajan E Sahin AA Chen JS Krishnamurthy RR Aggarwal N Brun AM Sapino A Zhang F Sharma D Yang XH Tora AD Mehta K Downregulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance Oncogene 2002 21 57 8843 8851 10.1038/sj.onc.1206044 12483536 · DOI
  52. Fong PC Xue WC Ngan HYS Chiu PM Chan KYK Tsao GSW Cheung ANY Caspase activity is downregulated in choriocarcinoma: a cDNA array differential expression study J Clin Pathol 2006 59 2 179 183 10.1136/jcp.2005.028027 16443735 PMC1860314 · DOI
  53. Lavrik I Golks A Krammer PH Death receptor signaling J Cell Sci 2005 118 265 267 10.1242/jcs.01610 15654015 · DOI
  54. Friesen C Fulda S Debatin KM Deficient activation of the CD95 (APO-1/Fas) system in drug resistant cells Leukaemia 1997 11 11 1833 1841 10.1038/sj.leu.2400827 9369415 · DOI
  55. Fulda S Los M Friesen C Debatin KM Chemosensitivity of solid tumour cells in vitro is related to activation of the CD95 system Int J Cancer 1998 76 1 105 114 10.1002/(SICI)1097-0215(19980330)76:1<105::AID-IJC17>3.0.CO;2-B 9533769 · DOI
  56. Fulda S Evasion of apoptosis as a cellular stress response in cancer Int J Cell Biol 2010 2010 370835 20182539 PMC2825553
  57. Reesink-Peters N Hougardy BM van den Heuvel FA Ten Hoor KA Hollema H Boezen HM de Vries EG de Jong S van der Zee AG Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study Gynaecol Oncol 2005 96 3 705 713 10.1016/j.ygyno.2004.10.046 15721415 · DOI
  58. Abou-Nassar K Brown JR Novel agents for the treatment of chronic lymphocytic leukaemia Clin Adv Haematol Oncol 2010 8 12 886 895 21326166
  59. Kang MH Reynolds CP Bcl-2 inhibitors Targeting mitochondrial apoptotic pathways in cancer therapy Clin Cancer Res 2009 15 1126 1132 10.1158/1078-0432.CCR-08-0144 19228717 PMC3182268 · DOI
  60. Oltersdorf T Elmore SW Shoemaker AR Armstrong RC Augeri DJ Belli BA Bruncko M Deckwerth TL Dinges J Hajduk PJ Joseph MK Kitada S Korsmeyer SJ Kunzer AR Letai A Li C Mitten MJ Nettesheim DG Ng S Nimmer PM O'Connor JM Oleksijew A Petros AM Reed JC Shen W Tahir SK Thompson CB Tomaselli KJ Wang B Wendt MD Zhang H Fesik SW Rosenberg SH An inhibitor of Bcl-2 family proteins induces regression of solid tumours Nature 2005 435 7042 677 681 10.1038/nature03579 15902208 · DOI
  61. Albershardt TC Salerni BL Soderquist RS Bates DJ Pletnev AA Kisselev AF Eastman A Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and upregulating BH3-only protein NOXA J Biol Chem 2011 286 28 24882 24895 10.1074/jbc.M111.255828 21628457 PMC3137063 · DOI
  62. Ocker M Neureiter D Lueders M Zopf S Ganslmayer M Hahn EG Herold C Schuppan D Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer Gut 2005 54 9 1298 1308 10.1136/gut.2004.056192 16099798 PMC1774673 · DOI
  63. Wu X Liu X Sengupta J Bu Y Yi F Wang C Shi Y Zhu Y Jiao Q Song F Silencing of Bmi-1 gene by RNA interference enhances sensitivity to doxorubicin in breast cancer cells Indian J Exp Biol 2011 49 2 105 112 21428211
  64. Roth JA Nguyen D Lawrence DD Kemp BL Carrasco CH Ferson DZ Hong WK Komaki R Lee JJ Nesbitt JC Pisters KM Putnam JB Schea R Shin DM Walsh GL Dolormente MM Han CI Martin FD Yen N Xu K Stephens LC McDonnell TJ Mukhopadhyay T Cai D Retrovirus-mediated wild-type p53 gene transfer to tumuors of patients with lung cancer Nature Medicine 1996 2 9 985 991 10.1038/nm0996-985 8782455 · DOI
  65. Chène P p53 as a drug target in cancer therapy Expert Opin Ther Patents 2001 11 6 923 935 10.1517/13543776.11.6.923 · DOI
  66. Suzuki K Matusubara H Recent advances in p53 research and cancer treatment J Biomed Biotech 2011 2011 978312 PMC3134396 21765642
  67. John Nemunaitis Ian Ganly Fadlo Khuri James Arseneau Joseph Kuhn Todd McCarty Stephen Landers Phillip Maples Larry Rome Britta Randlev Tony Reid Sam Kaye David Kirn Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial Cancer Res 2000 60 6359 11103798
  68. Boeckler FM Joerger AC Jaggi G Rutherford TJ Veprintsev DB Fersht AR Targeted rescue of a destabilised mutant of p53 by an in silico screened drug Proc Natl Acad Sci USA 2008 105 30 10360 10365 10.1073/pnas.0805326105 18650397 PMC2492497 · DOI
  69. Rippin TM Bykov VJ Freund SM Selivanova G Wiman KG Fersht A Characterisation of the p53-rescue drug CP-31398 in vitro and in living cells Oncogene 2002 21 14 2119 2129 10.1038/sj.onc.1205362 11948395 · DOI
  70. Shangary S Wang S Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy Annu Rev Pharmacol Toxicol 2008 49 223 241 PMC2676449 18834305
  71. Lain S Hollick JJ Campbell J Staples OD Higgins M Aoubala M McCarthy A Appleyard V Murray KE Baker L Thompson A Mathers J Holland SJ Stark MJ Pass G Woods J Lane DP Westwood NJ Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator Cancer Cell 2008 13 5 454 463 10.1016/j.ccr.2008.03.004 18455128 PMC2742717 · DOI
  72. Kuball J Schuler M Antunes Ferreira E Herr W Neumann M Obenauer-Kutner L Westreich L Huber C Wölfel T Theobald M Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man Gene Ther 2002 9 13 833 843 12080377
  73. Svane IM Pedersen AE Johnsen HE Nielsen D Kamby C Gaarsdal E Nikolajsen K Buus S Claesson MH Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study Cancer Immunol Immunother 2004 53 7 633 641 10.1007/s00262-003-0493-5 14985857 PMC11032806 · DOI
  74. Vermeij R Leffers N van der Burg SH Melief CJ Daemen T Nijman HW Immunological and clinical effects of vaccines targeting p53-overexpressing malignancies J Biomed Biotechnol 2011 2011 702146 21541192 PMC3085500
  75. Dai Y Lawrence TS Xu L Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-kappa B Am J Tranl Res 2009 1 1 1 15 PMC2776288 19966933
  76. Cao C Mu Y Hallahan DE Lu B XIAP and Survivin as therapeutic targets for radiation sensitisation in preclinical models of lung cancer Oncogene 2004 23 7047 7052 10.1038/sj.onc.1207929 15258565 · DOI
  77. Hu Y Cherton-Horvat G Dragowska V Baird S Korneluk RG Durkin JP Mayer LD LaCasse EC Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo Clin Cancer Res 2003 9 2826 2836 12855663
  78. Ohnishi K Scuric Z Schiesti RH Okamoto N Takahashi A Ohnishi T siRNA targeting NBS1 or XIAP increases radiation sensitivity of human cancer cells independent of TP53 status Radiat Res 2006 166 454 462 10.1667/RR3606.1 16972754 · DOI
  79. Yamaguchi Y Shiraki K Fuke H Inoue T Miyashita K Yamanaka Y Saitou Y Sugimoto K Nakano T Targeting of X-linked inhibitor of apoptosis protein or Survivin by short interfering RNAs sensitises hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death Oncol Rep 2005 12 1211 1316 16211302
  80. Grossman D McNiff JM Li F Altieri DC Expression and targeting of the apoptosis inhibitor, Survivin, in human melanoma J Invest Dermatol 1999 113 6 1076 1081 10.1046/j.1523-1747.1999.00776.x 10594755 · DOI
  81. Sharma H Sen S Lo ML Mraiggiò Singh N Antisense-mediated downregulation of antiapoptotic proteins induces apoptosis and sensitises head and neck squamous cell carcinoma cells to chemotherapy Cancer Biol Ther 2005 4 720 727 10.4161/cbt.4.7.1783 15917659 · DOI
  82. Du ZX Zhang HY Gao DX Wang HQ Li YJ Liu GL Antisurvivin oligonucleotides inhibit growth and induce apoptosis in human medullary thyroid carcinoma cells Exp Mol Med 2006 38 230 240 16819281
  83. Kami K Doi R Koizumi M Toyoda E Mori T Ito D Kawaguchi Y Fujimoto K Wada M Miyatake S Imamura M Downregulation of Survivin by siRNA diminishes radioresistance of pancreatic cancer cells Surgery 2005 138 2 299 305 10.1016/j.surg.2005.05.009 16153440 · DOI
  84. Liu Q Dong C Li L Sun J Li C Li L Inhibitory effects of the survivin siRNA transfection on human lung adenocarcinoma cells SPCA1 and SH77 Zhongguo Fei Ai Za Zhi 2011 14 1 18 22 21219826 PMC5999702
  85. Zhang X Li N Wang YH Huang Y Xu NZ Wu LY Effects of Survivin siRNA on growth, apoptosis and chemosensitivity of ovarian cancer cells SKOV3/DDP Zhonghua Zhong Liu Za Zhi 2009 31 3 174 177 19615253
  86. Yang CT Li JM Weng HH Li YC Chen HC Chen MF Adenovirus-mediated transfer of siRNA against Survivin enhances the radiosensitivity of human non-small cell lung cancer cells Cancer Gene Ther 2010 17 120 130 10.1038/cgt.2009.55 19730451 · DOI
  87. Pennati M Folini M Zaffaroni N Targeting Survivin in cancer therapy: fulfilled promises and open questions Carcinogenesis 2007 28 6 1133 1139 10.1093/carcin/bgm047 17341657 · DOI
  88. Sun H Liu L Lu J Qiu S Yang CY Yi H Wang S Cyclopeptide Smac mimetics as antagonists of IAP proteins Bioorg Med Chem Lett 2010 20 10 3043 3046 10.1016/j.bmcl.2010.03.114 20443226 PMC2997469 · DOI
  89. Lu J McEachern D Sun H Bai L Peng Y Qiu S Miller R Liao J Yi H Liu M Bellail A Hao C Sun SY Ting AT Wang S Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment Mol Cancer Ther 2011 10 5 902 914 10.1158/1535-7163.MCT-10-0864 21372226 PMC3091962 · DOI
  90. Rohn JL Noteborn MH The viral death effector Apoptin reveals tumour-specific processes Apoptosis 2004 9 315 322 15258463
  91. Philchenkov A Zavelevich M Kroczak TJ Los M Caspases and cancer: mechanisms of inactivation and new treatment modalities Exp Oncol 2004 26 2 82 97 15273659
  92. Yamabe K Shimizu S Ito T Yoshioka Y Nomura M Narita M Saito I Kanegae Y Matsuda H Cancer gene therapy using a pro-apoptotic gene, caspase-3 Gene Ther 1999 6 12 1952 1959 10.1038/sj.gt.3301041 10637446 · DOI
  93. Cam L Boucquey A Coulomb-L'hermine A Weber A Horellou P Gene transfer of constitutively active caspase-3 induces apoptosis in a human hepatoma cell line J Gene Med 2005 7 1 30 38 10.1002/jgm.636 15521050 · DOI
  94. Li X Fan R Zou X Gao L Jin H Du R Xia L Fan D Inhibitory effect of recombinant adenovirus carrying immunocaspase-3 on hepatocellular carcinoma Biochem Bioohys Res Commun 2007 358 2 489 494 10.1016/j.bbrc.2007.04.134 17502111 · DOI

Cited by

Sorted by citations

Authors
Wong, R. S.
Venue
Journal of Experimental & Clinical Cancer Research
Publisher
Springer Science and Business Media LLC
Published
2011-09-26
Volume
30
Issue
1
Pages
87-87
ISSN
  • 0392-9078 (ISSN-L)
  • 1756-9966
DOI
10.1186/1756-9966-30-87
PMC
PMC3197541
OpenAlex
W2158025958
Cited by
2,836
References
6
Citations by year
2026: 93 · 2025: 215 · 2024: 302 · 2023: 322 · 2022: 337 · 2021: 328 · 2020: 276 · 2019: 195 · 2018: 197 · 2017: 165 · 2016: 137 · 2015: 118 · 2014: 73 · 2013: 49 · 2012: 27
FWCI
4.35
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Experimental & Clinical Cancer Research (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Greater South Information System
Funders
International Medical University
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Health Sciences › Medicine › Pharmacology › Flavonoids in Medical Research
Keywords
apoptosis, cancer, apoptosis signaling, carcinogenesis, tumour metastasis, drug resistance, chemoresistance, malignant transformation
MeSH terms
Animals, Antineoplastic Agents, Humans, Neoplasms, Prognosis, Apoptosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review